Can Revenue Rise Aid Envision Healthcare (EVHC) Q4 Earnings?
Zacks Investment Research | Feb 22, 2018 10:30PM ET
Envision Healthcare Corp. (NYSE:EVHC) is expected to report fourth-quarter 2017 and full-year results on Feb 27, 2018. The company anticipates an increase in revenues from the company's Physician Services segment (contributing nearly 84% of the company’s revenues), driven by synergy from recent acquisitions as well as organic growth.
Revenue growth in the segment is likely to come from higher patient volumes as well as improved pricing. We also anticipate an improved EBIDTA, possibly benefiting from merger-related synergies. The Zacks Consensus Estimate for this segmental revenues is pegged at $1.65 billion compared with $865.8 million reported a year ago.
The company’s Ambulatory service segment will likely report decline in revenues due to disposal of centers. The Zacks Consensus Estimate for revenues from this segment stands at $324 million, down from $326.7 million reported in the year-ago quarter.
Moreover, the company is reeling under escalating operating expenses for several quarters on higher salaries and benefits expenses. Most alarming is the rate at which the metric rose, which has overshadowed the revenue growth rate, thwarting the company’s bottom-line growth in turn. The same is forecast in the to-be-reported quarter.
A huge debt load is also affecting Envision Healthcare. Its total debt burden has been swelling since 2013, leading to a spike in interest expense. This in turn might also dent the company’s operating margins.
Company's Preliminary Results
Earlier this February 2018, the company came up with preliminary fourth-quarter 2017 and full-year numbers. Envision Healthcare projects net revenues from continuing operations at approximately $2.0 billion and adjusted EBITDA at or slightly above the high end of its guided range of $182-$202 million.
Earnings Surprise History
The company has a mixed earnings history. It missed estimates in two of the trailing four quarters with an average negative surprise of 5.2%.
Envision Healthcare Corporation Price and EPS Surprise
Why a Likely Positive Surprise?
Our proven model shows that Envision Healthcare is likely to beat on earnings because it has the right combination of the following two important ingredients:
Zacks ESP: Envision Healthcare has an Earnings ESP Filter.
Zacks Rank: Envision Healthcare carries a Zacks Rank #3 (Hold). Notably, stocks with a solid Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 have a significantly higher chance of beating estimates.
Conversely, Sell-rated stocks (#4 or 5) should never be considered going into an earnings announcement, especially when the company is witnessing negative estimate revisions.
Other Stocks With Favorable Combination
Here are some other companies worth considering from the health care sector with the right combination of elements to deliver an earnings beat:
Get The News You Want
Teladoc Inc. (NYSE:TDOC) has an Earnings ESP of +28.98% and a Zacks Rank of 3. The company will report fourth-quarter earnings on Feb 27. You can see Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.